Skip to content

Clinical trials

Completed Multiple Myeloma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Myeloma Status: Completed Country / region: United States Clear all

1,122 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200035
200126
200235
200345
200450
200554
200643
200753
200860
200942
201064
201155
201265
201337
201450
201556
201644
201742
201833
201929
202023
202131
202214
202314
20249

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,122

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center61
National Cancer Institute (NCI)60
Mayo Clinic54
Memorial Sloan Kettering Cancer Center44
M.D. Anderson Cancer Center35
Celgene30
University of Arkansas30
Amgen22
Janssen Research & Development, LLC21
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins21

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Myeloma1,122
Neoplasms, Plasma Cell281
Lymphoma, Non-Hodgkin267
Hodgkin Disease244
Leukemia, Lymphocytic, Chronic, B-Cell238
Precursor Cell Lymphoblastic Leukemia-Lymphoma217
Lymphoma191
Leukemia, Myeloid, Acute189
Lymphoma, Follicular181
Lymphoma, Mantle-Cell181

Trials

Showing 1 to 25 of 1,122. Each trial links to its page on Pharma Observatory.

1,022 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.